CJC-1295 No DAC + Ipamorelin Blend (5mg/5mg) adds two well-researched growth hormone secretagogues in an equal ratio.
$78.00
Out of stock
Out of stock
CJC-1295 No DAC + Ipamorelin Blend (5mg/5mg) combines two well-researched growth hormone secretagogues in an equal 1:1 ratio. CJC-1295 (No DAC) (Mod GRF 1-29) functions as a short-acting GHRH analog, while Ipamorelin acts as a selective ghrelin mimetic and GHS-R agonist.
Together, in laboratory models, they support research into synergistic growth hormone release mechanisms, pulsatile secretion patterns, and downstream IGF-1 signaling.
Each vial contains 5mg CJC-1295 No DAC and 5mg Ipamorelin provided as a sterile lyophilized blend with ≥99% purity verified by HPLC.
This pre-mixed format simplifies reconstitution and dosing for in vitro assays, cell culture experiments, and small-animal research protocols.
The blend is intended exclusively for in vitro and in vivo laboratory research. It is not intended for human consumption, therapeutic use, or any non-research application.
For research use only. Strictly not for human consumption.
CJC-1295 No DAC (Mod GRF 1-29) is a 29-amino-acid GHRH analog with four substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) for enhanced stability and receptor affinity.
Ipamorelin is a pentapeptide ghrelin mimetic (Aib-His-D-2-Nal-D-Phe-Lys-NH₂).
The blend is provided as a single lyophilized powder containing equal parts of both peptides in acetate salt form.
This combination allows researchers to study complementary pathways including GHRH receptor activation and selective GHS-R stimulation with minimal off-target endocrine effects.
The CJC-1295 (No DAC) + Ipamorelin blend is used in endocrine, metabolic, and aging research to:
CJC-1295 (No DAC) binds to pituitary GHRH receptors and activates Gs-protein coupled signaling pathways.
This increases cyclic AMP, activates protein kinase A, and stimulates pulsatile growth hormone transcription and release.
Its short half-life (~30 minutes) mimics natural physiological GHRH pulses without continuous stimulation.
Ipamorelin selectively activates the ghrelin receptor (GHS-R1a), triggering rapid GH pulses through calcium mobilization and Gq-protein signaling.
Its receptor selectivity minimizes stimulation of prolactin, cortisol, or ACTH pathways.
CJC-1295 enhances GH pulse amplitude, while Ipamorelin increases pulse frequency, enabling investigation of synergistic GH/IGF-1 responses.
Preclinical and early clinical literature indicates enhanced GH secretion profiles when both peptides are combined.
In vitro pituitary studies demonstrate higher GH release compared to individual peptide exposure.
Rodent studies show increased IGF-1 levels while maintaining physiological pulsatility, alongside improvements in lean mass and metabolic markers.
Short-acting CJC-1295 avoids prolonged GH elevation associated with DAC variants.
Ipamorelin’s selective activity reduces unwanted endocrine effects.
Applications under investigation include wound healing, sarcopenia, metabolic regulation, and age-related endocrine decline.
There is currently no approved human therapeutic use; all findings remain investigational.
All batches undergo third-party analytical testing for purity, identity, and contaminant screening.
The CJC-1295 No DAC + Ipamorelin Blend (5mg/5mg) is an investigational compound intended solely for laboratory research and animal studies.
It is not approved by the FDA, EMA, or any regulatory authority for human therapeutic or diagnostic use.
Preclinical findings do not predict human outcomes, and no safety or efficacy claims are made.
Handle only within qualified research facilities under institutional biosafety oversight. Not for human or veterinary consumption.
This compound is intended for laboratory research use only. It is not intended for human or animal consumption, or for use in diagnostic or therapeutic procedures.
| Chemical Formula | CJC-1295 (No DAC): C152H252N44O42 Ipamorelin: C38H49N9O5 |
| Molecular Mass | CJC-1295 (No DAC): 3367.9 g/mol Ipamorelin: 711.9 g/mol |
| Monoisotopic Mass | CJC-1295 (No DAC): 3365.8935782 Da Ipamorelin: 711.38566570 Da |
| Polar Surface Area | CJC-1295 (No DAC): 1450 Ų Ipamorelin: 240 Ų |
| Complexity | CJC-1295 (No DAC): 7710 Ipamorelin: 1200 |
| XLogP | CJC-1295 (No DAC): -10.7 Ipamorelin: 1.8 |
| Heavy Atom Count | CJC-1295 (No DAC): 238 Ipamorelin: 52 |
| Hydrogen Bond Donor Count | CJC-1295 (No DAC): 52 Ipamorelin: 8 |
| Hydrogen Bond Acceptor Count | CJC-1295 (No DAC): 48 Ipamorelin: 8 |
| Rotatable Bond Count | CJC-1295 (No DAC): 118 Ipamorelin: 19 |
| CID | CJC-1295 (No DAC): 91976842 Ipamorelin: 9831659 |
| InChI | CJC-1295 (No DAC): InChI=1S/C152H252N44O42/c1-22-79(15)…(H4,164,165,168) Ipamorelin: InChI=1S/C38H49N9O5/c1-38(2,41)37(52)…/m0/s1 |
| InChIKey | CJC-1295 (No DAC): XOZMWINMZMMOBR-UHFFFAOYSA-N Ipamorelin: NEHWBYHLYZGBNO-BVEPWEIPSA-N |
| IUPAC Name | CJC-1295 (No DAC): 4-[[1-[[1-[[1-[[1-[[5-amino-1-[[1-[[1-[[1-[[6-amino-1-[[1-[[1-[[1-[[5-amino-1-[[1-[[1-[[1-[[1-[[6-amino-1-[[1-[[1-[[5-amino-1-[[1-[[1-[[1-[[1-[(1-amino-5-carbamimidamido-1-oxopentan-2-yl)amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoylamino]-4-oxobutanoic acid Ipamorelin: (2S)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[(2-amino-2-methylpropanoyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-3-phenylpropanoyl]amino]hexanamide |
| SMILES | CJC-1295 (No DAC): CCC(C)C(C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)O)C(=O)NC(CCC(=O)N)C(=O)NC(CO)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)N)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(C)NC(=O)C(CC3=CC=C(C=C3)O)N Ipamorelin: CC(C)(C(=O)NC@@HC(=O)NC@HC(=O)NC@HC(=O)NC@@HC(=O)N)N |
Every batch of CJC-1295 NO DAC (5mg) + Ipamorelin (5mg) Blend is tested for purity and identity using industry-standard methods.
High-Performance Liquid Chromatography confirms purity ≥99%. Each batch is analyzed to ensure consistent quality.
Identity verification via mass spectrometry confirms correct molecular weight of 4113.58 g/mol.
All compounds undergo independent third-party laboratory testing for quality assurance.
Certificate of Analysis documents are available for all compounds. Contact us with your order number to request batch-specific documentation.
Each compound batch is tested by independent laboratories to verify purity, identity, and quality. The Certificate of Analysis (COA) provides transparent lab results, ensuring the compound meets strict research-grade standards.
| Test | Method | Result | Specification | |
|---|---|---|---|---|
| Identity | HPLC-DAD | CJC-1295 (No DAC) / Ipamorelin | CJC-1295 (No DAC) / Ipamorelin | Pass |
| Purity | HPLC-DAD | 99.19 | >99% by HPLC | Pass |
| Quantity | HPLC Analyte Concentration Curve Assay | 5.15 / 5.11 | 5mg / 5mg | Pass |
| Endotoxins | LAL ELISA | 0.134 EU/mL | ≤ 0.5 EU/mL | Pass |
| Sterility | Pour Plate | No Growth | No Growth | Pass |
This site supplies research compounds strictly for laboratory research. You must confirm both statements below to enter.
Compounds are supplied for laboratory research use only and are not for human or veterinary use.
